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ABSTRACT 
The rise in infectious diseases as well as noninfectious immune related disorders causes millions of premature deaths worldwide and 
demands the need for the development of efficient immunomodulators. Consumer awareness about the harmful effects of chemical 
drugs raised a need to search for natural / alternative therapies for the treatment of diseases. Immunotherapy is one of the alternative 
ways of modification of diseases. Some bacterial cell components such as peptidoglycans, lipoteichoic acid, secreted soluble 
substances, genomic DNA, etc, play role in immunomodulation responses. Structural difference between bacterial and eukaryotic 
DNA apparently account for the ability of bacterial DNA to serve as an immune activating agent, because of its high content of 
unmethylated CpG dinucleotides. Probiotic DNA’s efficacy could be further enhanced by loading it onto nanoparticles. 
Nanoparticle-assisted delivery may be a promising approach to alleviate the problem of instability and degradation of DNA. The 
present study was conducted to prepare and characterize the probiotic DNA loaded chitosan nanoparticles (DLCNP) and to find out 
the anti-diabetic potential of probiotic bacterial DNA Lactobacillus acidophilus NCDC 343 (LA DNA). Therapeutic efficacy of 
Probiotic DNA loaded with Chitosan Nanoparticles was evaluated in treating diabetic Balb/c mice. DNA loaded Chitosan 
Nanoparticles proved as effective anti-diabetic agents and in addition, the bioactivity of probiotic DNA was improved through nano 
delivery. 
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INTRODUCTION 
An inactive life, which involves lack of 
exercise & poor calorie management, is one of the 
biggest contributors to the dreaded disease of diabetes. 
India is facing an epidemic of diabetes. At present 
confirmed diabetes patients in India are 62 million, with 
another 30 million pre-diabetes group. By 2030, 
diabetes mellitus may afflict up to 79.4 million 
individuals in India 
1
. Diabetes is not only a blood sugar 
problem, but brings along other complications as well. 
Diabetes can be treated by chemicals or drugs e.g. 
Pramlintide such as (SymlinPen 120, SymlinPen 60). 
But these drugs have various side effects also such as 
nausea 
2
, vomiting, and watery diarrhea, headache and 
indigestion, mild allergic reactions with rash, itchiness 
and fever, problems with the kidneys, liver, lungs and 
pancreas. But due to their various side effects and 
consumer awareness, people are moving towards natural 
and safe means for treating the diseases. 
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Immunotherapy using probiotics could be one 
of the safe strategies for treating diabetes. As probiotics 
are proved immunomodulators and have been given a 
GRAS status (Generally Regarded As Safe), hence the 
immunomodulation through probiotics has been selected 
for the study. Probiotics are important for the 
development as well as maintenance of innate and 
adaptive immunity, digestive and metabolic actions, and 
discourage the colonization of pathogens
3
. Probiotics 
have been emerging as important alternatives for the 
replacement of these food additives 
4,5
. 
Prokaryotic cell components consist of 
peptidoglycans, lipo-teichoic acid, some other secreted 
soluble substances and genomic DNA which can act as 
immunomodulatory agents. The probiotic genomic 
DNA as also proved to be immunomodulatory 
6,7
. 
Prokaryotic DNA when enters the eukaryotic cells, 
serves as immune-modulator or immune activating 
agent. Short sequences with unmethylated CpG 
dinucleotides present in the bacterial DNA are 
responsible for the immune-modulatory changes. 
Oligodeoxynucleotides (ODN) containing CpG motifs 
activate the host defense mechanisms which lead to the 
innate and acquired immune responses. As the naked 
DNA is degraded in the body systems because of the 
presence of nucleases in the serum, hence the 
availability of DNA into the cells of body, reduces, due 
to which it needs to be loaded onto different materials 
8
. 
Nanoparticles are arising as one of the exciting 
tools for this purpose. Different materials can be used 
for the coating in nanotechnology e.g. Gold, Silver, 
PLGA, Chitosan, etc. Chitosan is preferred over Gold 
nanoparticles because it has unique properties such as 
less or negligible toxicity, being cost effective, 
biodegradability & stability; high transfection 
efficiency, muco-adhesive properties and easy 
permeation into the cell wall 
9
.  
As the DNA is negatively charged, it interacts with the 
positively charged chitosan. Thus, Chitosan can form 
complexes with DNA easily. In the small intestines, it 
has the capacity to open up the tight junctions and 
protect the DNA from its degradation very effectively. 
Hence it serves as a good carrier for gene delivery
10
. 
Chitosan Nanoparticles have also shown to be having 2 
times more immune enhancing activity as compared to 
hydrocortisone treated experimental animals
11
. Hence, 
the present study was planned to prepare, characterize 
and evaluate the antidiabetic efficacy of probiotic DNA 
loaded chitosan nanoparticles and its improvement 
through nanodelivery. 
MATERIAL AND METHODS 
Probiotic strain: Lactobacillus acidophilus NCDC343 
(LA 343) was procured from NDRI, Karnal. The culture 
so obtained were given two revival cycles in de Man–
Rogosa–Sharpe broth (MRS broth) at 37°C and 
maintained for further use.  
Isolation of Genomic DNA from LA 343: For genomic 
DNA preparation, cells were grown in MRS broth 
containing 1.5 % glycine to facilitate cell lysis. Genomic 
DNA was isolated 
12
 and its quality was checked by 
agarose gel electrophoresis and quantity was determined 
spectrophotometerically. 
Preparation of Chitosan Nanoparticles (CNP) and 
DNA loaded Chitosan Nanoparticles (DLCNP) 
Purifiaction of Chitosan was performed according to
13
. 
Further, Chitosan and DNA loaded Chitosan 
Nanoparticles were prepared according to protocol given 
by Silva et al
14
 and Akbuga et al
15
 respectively. 
Characterization of DLCNP 
Characterization studies were performed through 
various experiments: Agarose gel electrophoresis (to 
determine complexed DNA), Loading efficiency and 
Loading capacity, SEM, TEM and Dynamic Light 
Scattering (to determine Size and Zeta potential) of 
Nanoparticles.  
Therapeutic potential of Probiotic DNA loaded 
Chitosan Nanoparticles against Diabetes 
Induction of Experimental Diabetes 
16
 
The Balb/c mice  were divided into respective 
groups each of minimum six animals, housed 
individually in the departmental animal house and were 
exposed to 12 hr cycle of light and dark. The 
experimental protocol was approved by Institutional 
Animal Ethical Committee (Registration 
No:107/99/CPCSEA/2014-21.Experiments were carried 
out as per the guidelines of committee for Purpose of 
Control and Supervision of Experiments on Animals 
(CPCSEA) Ministry of Environment and Forest, 
Government of India. 
Experimental diabetes was induced by intra-
peritoneal (i.p.) 
17
 administration of alloxan 
monohydrate in mice which had been subjected to 
overnight fasting. Total dose of alloxan (150 mg/kg b. 
wt.) was administrated in three injections at intervals of 
24h (50 mg/kg b.wt.). Animals showing blood glucose 
level above 200mg/dL (diabetic) were selected for 
further study. 
Experimental design 
Diabetic Balb/c mice were divided into 8 groups (n=6). 
Group 1was Normal Control and groups 2-8 were made 
hyperglycemic by alloxan. 
Group 1: Normal Control (Normal Diet) i.e. mice fed 
with basal feed. 
Group 2: Hyperglycemic mice i.e. Untreated Negative 
Control fed with basal feed. 
Group 3: Hyperglycemic mice dosed with 
Glybenclamide 10mg/kg b.wt. on consecutive days. 
Group 4: Hyperglycemic mice dosed with LA DNA at 
the rate of 75µg DNA per mouse.* 
Group 5: Hyperglycemic mice dosed with DLCNP at 
the rate of 80µg DNA per mouse.* 
Group 6: Hyperglycemic mice dosed with CNP.* 
Group 7: Hyperglycemic mice were dosed with 
DLCNP, each dose containing 80µg DNA per mouse & 
Glybenclamide (10mg/kg b.wt) * 
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Group 8: Hyerglycemic mice dosed with LA DNA, 
each dose containing 75µg DNA per mouse & 
Glybenclamide (10mg/kg b.wt) * 
* 5 injections, intra-peritoneally 
17
 at an interval of 6 
days. 
Collection of blood and determination of blood 
glucose 
Blood of control & experimental mice was 
collected from orbital sinus puncture using a heparinized 
capillary glass tube. The blood samples so collected 
were analyzed for blood glucose levels by glucose 
estimation kit (Gluco Dot Blood Glucose Monitoring 
System by Deep Meditech Pvt.Ltd.) 
Experiment involved the acute & sub-acute 
study. The acute study involved the estimation of blood 
glucose levels at 0, 2, 6 and 12 hours after 
administration of LA 343, LA DNA, Standard market 
available drug Glybenclamide, CNP, DLCNP and 
combinations with all the doses given at one time. The 
sub-acute study involved the repeated administration of 
drug for 28 days at a prefixed time and blood glucose 
levels were estimated on days 7, 14, 21 and 28. The data 
were represented as mean blood glucose level and 
standard error mean (SEM). 
The NBT reduction test was also performed to 
measure the neutrophil function 
18
. Determination of NO 
in serum was performed by the measurement of stable 
decomposition product nitrite (NO2) employing the 
Griess Reagent 
19
. 
RESULTS 
Characterization of DNA loaded Chitosan 
Nanoparticles 
The DLS experiment indicated that nanoparticles size 
ranging from to 276.5 to 351.7 nm were prepared with a 
positive zeta potential in between +12.6 to +17.7mV. 
Scanning Electron Microscopy revealed the shape & the 
size of the Chitosan Nanoparticles. The particles 
observed were oval or spherical in shape and the range 
was between 200 – 800nm. Transmission Electron 
Microscopy showed the size of the Chitosan 
Nanoparticles ranging from 30 to 50nm. Loading 
capacity and loading efficiency was observed to be 
0.18% was 97% respectively. 
 
Anti-Diabetic Activity 
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Figure 1: Effect of the sub-acute treatment of LA DNA, DLCNP, Drug Control & their combinations [LA DNA & 
Drug, DLCNP & Drug] on Blood Glucose level in Alloxan induced diabetes in mice. Blood Glucose levels were 
assessed at regular intervals of hours 0, 2, 4, 7, 12. Results are presented as mean ± SEM (n=6). 
 
Administration of the probiotic LA 343, CNP, 
DLCNP, Drug (Glybenclamide 10mg/kg b.wt.) and 
combinations of (LA 343 +Drug) and (DLCNP + Drug) 
significantly reduced blood glucose levels at 2,4,7,12 
hours. The Untreated Control and CNP showed almost 
same glucose level from 0-12 hours. Between 6 – 8 hrs, 
LA DNA treated animals showed hypoglycemic effect 
which was 4% higher than the drug treated animals i.e. 
LA DNA and drug decreased glucose level by 35.34% 
and 31.09% respectively. DLCNP treated animals 
showed better hypoglycemic effect as compared to LA 
DNA treated group. Glucose level reduction in former 
was found to be 49.85% which was higher than that 
observed in later i.e. 35.34%. When drug was used in 
combination with LA DNA and DLCNP, it was found 
that hypoglycemic effect in case of both groups, was 
higher than the animals treated with DLCNP and LA 
DNA alone i.e. (DLCNP + drug) showed hypoglycemic 
effect of 55.07% and (LA DNA + drug) showed 
41.01%.
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Sub-acute treatment 
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Figure 2: Effect of the sub-acute treatment of LA DNA, DLCNP, Drug Control & their combinations [LA DNA & 
Drug, DLCNP & Drug] on Blood Glucose level in Alloxan induced diabetes in mice.  Blood Glucose levels were 
assessed at regular intervals of days 0, 7, 14, 21, 28. Results are presented as mean ± SEM (n=6). 
 
Sub-acute administration of DNA LA343, Drug 
(Glybenclamide 10mg/kg b.wt) and the combination as 
(LA 343 + Drug) and (DLCNP + Drug) caused a 
significant reduction in the blood glucose levels as 
compared to control .In the Untreated Control, blood 
glucose level decreased slowly by low percentage of 
24.15%. The effect shown by untreated control as well 
as CNP was almost same. CNP also showed the 
hypoglycemic effect of 26.17% which was slightly 
higher than that of the untreated control. LA DNA 
gradually reduced blood glucose level by 52.05% within 
28 days. The drug Glybenclamide (Positive Control), 
showed a hypoglycemic effect of 56.24% which was 4% 
higher than LA DNA treated group. The animals treated 
with DLCNP as well as its combination with drug 
showed less reduction in blood glucose level upto 14 
days. After 15th day, faster reduction in the blood 
glucose was observed in both the test samples (DLCNP 
and DLCNP + drug) i.e. 62.17% and 66.07% 
respectively, till it reached normal blood glucose level at 
28th day. Alone DLCNP was slightly less effective than 
its combination with drug.  
NBT reduction test in blood 
There was a parallel increase in glucose level 
and neutrophil’s activity in the diabetic animals at the 
start of 28 day study. As, the glucose level decreased, 
due to therapeutic potential of test samples, neutrophil’s 
activity also decreased and attained normal level at the 
end of 28
th
 day. 
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Figure 3: Effect of LA DNA, DLCNP, Drug Control & their combinations [LA DNA & Drug, DLCNP & Drug] on 
NBT reduction in blood in Alloxan induced diabetes in mice. Blood was collected and assessed for NBT reduction on 
day 0, 15 and 28. Results are represented as mean ± SEM (n=6). 
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Disease control (hyperglycemic animals) 
showed the maximum Neutrophil’s activity (25.22 %) as 
compared to the normal control (10.69%) and all other 
(drug, LA DNA and DLCNP treated) groups. The drug 
Glybenclamide alone showed 21.3% neutrophil’s 
activity within 20 days of treatment which further 
reduced to 11.35%. Neutrophil’s activity of 22.83% at 
20
th
 day and 15.68% at 28
th
 day in LA DNA treated 
group was observed, both of which were slightly higher 
than drug treated group. DLCNP treated groups showed 
Neutrophil’s activity with maximum increase of 18.37% 
at 20
th
 day and 10.51% at 28
th
 day as compared to the 
previous discussed groups. 
Determination of Serum Nitric Oxide concentration 
(µg/ml) 
The drug treated group showed the maximum 
serum nitric oxide concentration of 49.31µg/ml, which 
was significantly higher than that observed in the 
normal control 3.58µg/ml. The Nitrite ions 
concentration in drug treated was 49.82 µg/ml. The 
untreated control showed the concentration of 
101.75µg/ml. DLCNP showed higher concentration than 
that of LA DNA. The DLCNP had concentration of 
18.24µg/ml and the LA DNA showed concentration of 
46.31µg/ml.
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Figure 4: Effect of LA DNA, DLCNP, Drug Control & their combinations [LA DNA & Drug, DLCNP & Drug] on 
Serum Nitrite Oxide concentration in Alloxan induced diabetes in mice. Blood was collected and serum was separated 
for determinations of serum nitric oxide concentration at day 0, 15, 28. Results are represented as mean ± SEM (n=6). 
 
DISCUSSION 
Diabetes is a dreadful disease and the rise in the 
patients suffering from this disease raises an alarm. 
Diabetes can be treated by chemical based drugs, which 
do have side effects of allergies, nausea, skin irritation, 
itching, rashes, drowsiness and dry mouth etc. Hence, a 
need is felt to find the alternative therapeutic agents. 
Immune modulation is one of the safe modes of 
managing diseases. In the present project attempt has 
been made to apply the immune modulation properties 
of probiotic DNA as a cure for diabetes.  
Immunomodulation using probiotics is like 
Lactobacillus, Bifidobacterium has already been 
documented 
20, 21, 22
. Even the DNA of probiotics has 
immunomodulatory potential 
6, 7, 23
. Since DNA is prone 
to nuclease degradation, hence it is protected by loading 
onto Nanoparticles. The Chitosan, Gold, PLGA, Silver 
etc. are highly compatible with DNA for its 
encapsulation. Because Chitosan is natural polymer, cost 
effective & is biodegradable 
10
, it is preferred over all 
other polymers. It is also a hydrophilic carrier system. 
The genomic DNA was isolated from LA 343 
& was subjected to in-vivo tests for anti-diabetic 
potential by Glucometer and it was characterized by 
employing the NBT, iNOS tests. The NBT (Nitroblue 
Tetrazolium reduction) test is an indicator of the oxygen 
dependent bactericidal activity of phagocytosis 
24
. NBT 
dye with low reduction potential when phagocytosed is 
reduced to formazon that can be measured 
spectrophotometrically 
25
. 
The possible mechanism behind this approach 
may be that the administration of the DNA loaded 
Chitosan Nanoparticles or LA 343 DNA showed a 
significant upregulation of Th-1 cytokine. T helper (Th) 
lymphocyte balance is crucial in regulating the 
appropriate cytokine response & hence remains as one 
of the targets for immunomodulation & immune based 
therapies. Thus, the optimal immunotherapy should 
restore or maintain a well-balanced Th1 and Th2 
response, suited to the immune challenge. Similar to the 
observations of the present study, earlier researchers 
have observed that Probiotics DNA stimulate the Th1 
mediated immune response 
26
. Thus present study was 
planned to load the probiotic DNA onto Chitosan 
Nanoparticles & evaluate the anti-diabetic potential. 
Therefore, five groups of the animals were set up as 
follows and were treated as: LA DNA, DLCNP, CNP, 
LA DNA + Drug and DLCNP + Drug. The 
administration of DLCNP in alloxan induced diabetic 
animals showed better hypoglycemic effect as indicated 
in acute (0 to 12 hrs) as well as sub-acute study (0 to 28 
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days). The animals treated with DLCNP as well as its 
combination with drug showed less reduction in blood 
glucose level than LA DNA and its combination with 
drug, upto 14 days; but faster reduction in the blood 
glucose was observed after 15
th
 day in both the former 
groups. 
The NBT test (Nitroblue Tetrazolium 
Reduction) test is an indicator of the respiratory burst 
and the nitric oxide test indicates the non-oxidative 
mechanism of killing of microbes.  NBT is an indirect 
marker of the measure the neutrophil function. 
Whenever a particle is ingested by a phagocyte,a 
respiratory burst is induced. The assay was based on the 
reaction that addition of yellow colored NBT dye to 
neutrophils results in the formation of complex which 
can be phagocytosed by neutrophils. The yellow colored 
NBT was reduced to the blue colored formazone which 
can be extracted in Dioxan. Griess reaction involved the 
formation of a chromophore during the reaction of nitric 
oxide (NO2) with sulphanilamide and heterocyclic amine 
of N-(1-napthyl) ethylenediamine (Griess reagent) under 
conditions of low pH. During this reaction acidified 
nitrite undergoes diazotization with sulphanilamide to 
form diazonium salt. This diazonium salt then coupled to 
N-(1-napthyl) ethylenediamine to form magenta colored 
compound with a characteristic absorption spectrum. 
Underlying mechanism behind this approach is 
proposed to be because of the unmethylated CpG motifs. 
It was noted that the genomes of the bacterial and viral 
DNA contain much higher frequency of unmethylatedCp 
G dinucleotides than those of vertebrates. The DNA 
interacts with the ligand polycation Chitosan and forms 
the DNA-Chitosan complex which is endocytosed and 
further binds to receptors like TOL like receptor 9 & 
interacts with the cell membrane inside the cell. The 
endosome formed releases its components inside the cell 
that are taken up by nucleus through trafficking and 
leads to the activation of various immune cells & 
production of cytokines. The balance of Th1 & Th2 
cytokines plays role in enhancing the 
immunomodulatory potential & treating various 
diseases. 
27
 
The combination of the drug Glybenclamide 
and DNA of LA 343 showed significantly higher 
hypoglycemic effect of as compared to the drug 
Glybenclamide alone. Hence, the results show that the 
interaction between the probiotic DNA and the Chitosan 
Nanoparticles showed the maximum anti-diabetic 
potential in the host body system. Moreover studies have 
shown that probiotics reduced the blood glucose levels 
28, 29
 and there is a co-relation between blood glucose 
level and immune-modulation 
30
. Hence, our study 
highlights that to get immune effects, it is not necessary 
to give whole bacterial1 cell in the diabetic host instead 
genomic DNA of probiotic cell can also be used as a 
safe anti-diabetic agent. Moreover, the results indicate 
that probiotic genomic DNA loaded onto nanoparticles 
enhance the anti-diabetic potential of DNA. 
Abbreviations 
CpG-ODNs: Oligodeoxynucleotides containing CpG motifs 
LA 343: Lactobacillus acidophilus NCDC343 
LA DNA: Genomic DNA isolated from LA 343 
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DLCNP: Probiotic DNA loaded Chitosan Nanoparticles 
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